IQVIA Holdings Inc IQV

RESEARCH TRIANGLE PARK, N.C., September 29, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompany

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

IQVIA Holdings (IQV) has just priced a US$2b senior notes offering due 2034, a sizable refinancing move that reshapes its debt stack and gives investors fresh information on the company’s funding costs and capital structure. Over the past year IQVIA Holdings has delivered a 42.3% total shareholder return, with the share price up 58.8% over the last 90 days and 6.9% over the past month. The recent 1.1% daily pullback to US$266.42 therefore looks more like a pause after strong momentum than a...

IQVIA Holdings has delivered a strong share-price run recently, which naturally puts more focus on whether the cash it is expected to generate can support the current valuation. With the stock now trading in a different zone to where it sat a year ago, the question is how that move lines up with its underlying cash flows. The share price is up 42.3% over the past year, which puts real pressure on the cash flow story to justify where IQVIA sits today. The company has priced a US$2b senior...

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]

IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the "Notes"). The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees an

RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the "Notes").

The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

RESEARCH TRIANGLE PARK, N.C., September 03, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.

While most software companies were retreating, Paycom made an aggressive and unconventional bet on itself, and the market delivered a verdict that caught even seasoned analysts off guard.

The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.

Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...